|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.9 USD | +0.34% |
|
+24.30% | -20.89% |
| 05-09 | Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| 05-09 | Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000 | MT |
Feb 13 (Reuters) - Shares of obesity drug developer Altimmune fell 10% to $9.36 on Tuesday, after Kerrisdale Capital took a short position on the company's stock.
Altimmune did not immediately respond to a request for comment. (Reporting by Khushi Mandowara in Bengaluru; Editing by Krishna Chandra Eluri)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.89% | 629M | |
| +8.29% | 113B | |
| +10.21% | 106B | |
| +0.41% | 22.27B | |
| -11.90% | 22.22B | |
| -5.99% | 19.43B | |
| -37.36% | 17.87B | |
| -5.17% | 17.24B | |
| +7.70% | 14.29B | |
| +37.65% | 12.52B |
ALTIMMUNE, INC. 
